Phase III trial of MBP8298 for SPMS Enrolled
Submitted by art on Mon, 2007-01-29 07:23.
The trial, named MAESTRO-01, will include approximately 550 patients
at 48 trial sites in 10 countries. The Company remains on track to
receive interim data in mid-2008 from the first 200 patients enrolled,
when they have completed the 24 months of treatment. MBP8298 is
administered via an IV given only 2 times per year. It's good to see a
drug being tried in secondary progressive MS for a change.